Mallia Aesthetics conducts two consumer studies on hair and eyelash growth with 8T3 serums based on sCD83

• Studies evaluate the effects of 8T3 Essentials Hair Serum and 8T3 Essentials Lash & Brow Serum, two innovative hormone-free serums for hair and eyelash growth
• Both serums are based on MAL-838, a variant of the human sCD83 protein supported by decades of scientific research
• Initial results for 8T3 Essentials Lash & Brow Serum are expected in fall 2025

Erlangen, Germany, September 02, 2025 - Mallia Aesthetics GmbH, a company focusing on the development and commercialization of cosmetic products to stimulate hair growth, is conducting two consumer studies evaluating 8T3 Essentials Hair Serum and 8T3 Essentials Lash & Brow Serum. Both novel hormone-free topical serums are based on MAL-838, a proprietary variant of the soluble human protein CD83 (sCD83).

The study of 8T3 Essentials Hair Serum will be conducted over a period of six months with male test subjects. The aim is to establish the effect of consistent application of the serum on hair density and thickness. Changes will be accurately recorded and evaluated using precise image analysis methods.

A further consumer study is assessing the effects of once-daily application of 8T3 Essentials Lash & Brow Serum over a twelve-week period and will evaluate eyelash length, volume and thickness using state-of-the-art standardized imaging technology by Canfield Scientific.

Recruitment for both studies has already been completed, and both studies are underway.

“It is very exciting to see products based on our scientific work on sCD83 progressing into this new important phase of development with application by human volunteers. This marks a meaningful step toward advancing our research toward real-world cosmetic use, and we look forward to seeing how the biological effects we’ve studied translate into visible benefits in cosmetic applications,” said Prof. Dr. Alexander Steinkasserer, Co-founder and Managing Director of Mallia Innovations.

Dr. Anne Asmuß, Managing Director of Mallia Aesthetics, said: “We especially appreciate the support from Canfield Scientific, whose advanced imaging systems and methodological expertise enable us to objectively assess the efficacy of serum application. We expect initial results of the study with 8T3 Essentials Lash & Brow Serum in the fall, which will provide valuable insights into product performance and user perception. We remain on track to launch our first MAL-838 based cosmetic products in 2025.”

The 8T3 product line contains the active ingredient MAL‑838, which is based on the soluble CD83 protein. Scientific research by Mallia co-founder Prof. Dr. Alexander Steinkasserer and his team has shown that sCD83 has immunomodulatory and anti-inflammatory properties and can promote new hair growth. Mallia Aesthetics is developing a portfolio of cosmetic products based on MAL-838 that leverage this mechanism of action for effective hair growth stimulation.

About sCD83

Soluble CD83 (sCD83) is an immunomodulatory protein that is currently being developed for the topical treatment of hair loss (MAL‑856) and stimulation of hair growth (MAL‑838). The soluble CD83 protein was first identified in 2001 by Mallia co-founder Prof. Steinkasserer. It has anti-inflammatory properties via the induction of resolution of inflammation, which promotes wound healing and induces new hair growth.¹ In addition, sCD83 has been shown to activate regulatory T cells (Tregs)², which interact directly with hair follicles and can activate them.³ Furthermore, sCD83 inhibits cell death of hair follicles and directly activates follicular stem cells, thereby stimulating new hair growth. This multimodal mode of action distinguishes sCD83 from other topically applied hair growth agents.

Topically applied, sCD83 can directly reach the hair follicles but does not penetrate through the skin and thus does not enter the bloodstream. The effect is localized, which is a major advantage over systemic treatment options, which can cause severe side effects.

About Mallia

Mallia Innovations GmbH, based in Erlangen, Germany, is the holding company strategically driving the proprietary development and commercialization of biopharmaceutical therapies and cosmetic applications of the immune modulatory sCD83 protein, targeting hair growth, hair loss and other dermatological indications, including wound healing.

Mallia Therapeutics GmbH focuses on the clinical development of novel therapies for patients suffering from androgenetic alopecia or alopecia areata, among other conditions. MAL-856 is based on the scientifically proven immune modulatory mode of action of sCD83, which has been investigated for close to 25 years by Mallia Co‑founder Prof. Dr Alexander Steinkasserer.⁴

Mallia Aesthetics GmbH focuses on cosmetic applications for the stimulation of hair growth, which are also based on the scientifically validated sCD83 protein. The Company develops Innovative cosmetic products using MAL-838 that will be marketed to specialists and consumers.

For more information, visit www.mallia.com, follow us on LinkedIn.

¹ Royzman, D., Peckert-Maier, K., Stich, L., König, C., Wild, A. B., Tauchi, M., ... & Steinkasserer, A. (2022). Soluble CD83 improves and accelerates wound healing by the induction of pro-resolving macrophages. Frontiers in Immunology, 13, 1012647. DOI: 10.3389/fimmu.2022.1012647

² Bock, F., Rössner, S., Onderka, J., Lechmann, M., Pallotta, M. T., Fallarino, F., ... & Zinser, E. (2013). Topical application of soluble CD83 induces IDO-mediated immune modulation, increases Foxp3+ T cells, and prolongs allogeneic corneal graft survival. The Journal of Immunology, 191(4), 1965-1975. DOI: 10.4049/jimmunol.1201531

³ Ali, N., Zirak, B., Rodriguez, R. S., Pauli, M. L., Truong, H. A., Lai, K., ... & Rosenblum, M. D. (2017). Regulatory T cells in skin facilitate epithelial stem cell differentiation. Cell, 169(6), 1119-1129. DOI: 10.1016/j.cell.2017.05.002

⁴ Lechmann, M., Krooshoop, D. J., Dudziak, D., Kremmer, E., Kuhnt, C., Figdor, C. G., ... & Steinkasserer, A. (2001). The extracellular domain of CD83 inhibits dendritic cell–mediated T cell stimulation and binds to a ligand on dendritic cells. The Journal of experimental medicine, 194(12), 1813-1821. DOI: 10.1084/jem.194.12.1813